Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Cederkrantz, E, Angenete, E, Bäck, T, Falk, P, Haraldsson, B, Ivarsson, M-L, Jensen, H, Lindegren, S, Hultborn, R & Jacobsson, L 2012, 'Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At' Cancer Biotherapy & Radiopharmaceuticals, vol. 27, no. 6, pp. 353-64. https://doi.org/10.1089/cbr.2012.1184

APA

Cederkrantz, E., Angenete, E., Bäck, T., Falk, P., Haraldsson, B., Ivarsson, M-L., ... Jacobsson, L. (2012). Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At. Cancer Biotherapy & Radiopharmaceuticals, 27(6), 353-64. https://doi.org/10.1089/cbr.2012.1184

CBE

Cederkrantz E, Angenete E, Bäck T, Falk P, Haraldsson B, Ivarsson M-L, Jensen H, Lindegren S, Hultborn R, Jacobsson L. 2012. Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At. Cancer Biotherapy & Radiopharmaceuticals. 27(6):353-64. https://doi.org/10.1089/cbr.2012.1184

MLA

Vancouver

Author

Cederkrantz, Elin ; Angenete, Eva ; Bäck, Tom ; Falk, Peter ; Haraldsson, Börje ; Ivarsson, Marie-Louise ; Jensen, Holger ; Lindegren, Sture ; Hultborn, Ragnar ; Jacobsson, Lars. / Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At. In: Cancer Biotherapy & Radiopharmaceuticals. 2012 ; Vol. 27, No. 6. pp. 353-64.

Bibtex

@article{df61ebf75418465e9952382ec50aaaea,
title = "Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At",
abstract = "The introduction of the short-lived α-emitter (211)At to intraperitoneal radioimmunotherapy has raised the issue of the tolerance dose of the peritoneum. The short range of the α-particles (70 μm) and the short half-life (7.21 h) of the nuclide yield a dose distribution in which the peritoneum is highly irradiated compared with other normal tissues. To address this issue, mice were injected with (211)At-trastuzumab to irradiate the peritoneum to absorbed doses ranging between 0 and 50 Gy and followed for up to 34 weeks. The peritoneum-to-plasma clearance of a small tracer, (51)Cr-ethylenediamine tetraacetic acid, was measured for evaluation of the small solute transport capacity of the peritoneal membrane. The macroscopic status of the peritoneum and the mesenteric windows was documented when the mice were sacrificed. Biopsies of the peritoneum were taken for morphology and immunohistochemical staining against plasminogen activator inhibitor-1 and calprotectin. Peritoneum-to-plasma clearance measurements indicated a dose-dependent decrease in peritoneal transport capacity in irradiated mice. However, macroscopic and microscopic evaluations of the peritoneal membrane showed no difference between irradiated mice versus controls. The results imply that the peritoneal membrane tolerates absorbed doses as high as 30-50 Gy from α-particle irradiation with limited response.",
keywords = "Alpha Particles, Animals, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Astatine, Female, Immunohistochemistry, Immunotoxins, Mice, Mice, Inbred BALB C, Peritoneum, Radioimmunotherapy, Radiopharmaceuticals",
author = "Elin Cederkrantz and Eva Angenete and Tom B{\"a}ck and Peter Falk and B{\"o}rje Haraldsson and Marie-Louise Ivarsson and Holger Jensen and Sture Lindegren and Ragnar Hultborn and Lars Jacobsson",
year = "2012",
doi = "10.1089/cbr.2012.1184",
language = "English",
volume = "27",
pages = "353--64",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann/Liebert, Inc. Publishers",
number = "6",

}

RIS

TY - JOUR

T1 - Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At

AU - Cederkrantz, Elin

AU - Angenete, Eva

AU - Bäck, Tom

AU - Falk, Peter

AU - Haraldsson, Börje

AU - Ivarsson, Marie-Louise

AU - Jensen, Holger

AU - Lindegren, Sture

AU - Hultborn, Ragnar

AU - Jacobsson, Lars

PY - 2012

Y1 - 2012

N2 - The introduction of the short-lived α-emitter (211)At to intraperitoneal radioimmunotherapy has raised the issue of the tolerance dose of the peritoneum. The short range of the α-particles (70 μm) and the short half-life (7.21 h) of the nuclide yield a dose distribution in which the peritoneum is highly irradiated compared with other normal tissues. To address this issue, mice were injected with (211)At-trastuzumab to irradiate the peritoneum to absorbed doses ranging between 0 and 50 Gy and followed for up to 34 weeks. The peritoneum-to-plasma clearance of a small tracer, (51)Cr-ethylenediamine tetraacetic acid, was measured for evaluation of the small solute transport capacity of the peritoneal membrane. The macroscopic status of the peritoneum and the mesenteric windows was documented when the mice were sacrificed. Biopsies of the peritoneum were taken for morphology and immunohistochemical staining against plasminogen activator inhibitor-1 and calprotectin. Peritoneum-to-plasma clearance measurements indicated a dose-dependent decrease in peritoneal transport capacity in irradiated mice. However, macroscopic and microscopic evaluations of the peritoneal membrane showed no difference between irradiated mice versus controls. The results imply that the peritoneal membrane tolerates absorbed doses as high as 30-50 Gy from α-particle irradiation with limited response.

AB - The introduction of the short-lived α-emitter (211)At to intraperitoneal radioimmunotherapy has raised the issue of the tolerance dose of the peritoneum. The short range of the α-particles (70 μm) and the short half-life (7.21 h) of the nuclide yield a dose distribution in which the peritoneum is highly irradiated compared with other normal tissues. To address this issue, mice were injected with (211)At-trastuzumab to irradiate the peritoneum to absorbed doses ranging between 0 and 50 Gy and followed for up to 34 weeks. The peritoneum-to-plasma clearance of a small tracer, (51)Cr-ethylenediamine tetraacetic acid, was measured for evaluation of the small solute transport capacity of the peritoneal membrane. The macroscopic status of the peritoneum and the mesenteric windows was documented when the mice were sacrificed. Biopsies of the peritoneum were taken for morphology and immunohistochemical staining against plasminogen activator inhibitor-1 and calprotectin. Peritoneum-to-plasma clearance measurements indicated a dose-dependent decrease in peritoneal transport capacity in irradiated mice. However, macroscopic and microscopic evaluations of the peritoneal membrane showed no difference between irradiated mice versus controls. The results imply that the peritoneal membrane tolerates absorbed doses as high as 30-50 Gy from α-particle irradiation with limited response.

KW - Alpha Particles

KW - Animals

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Agents

KW - Astatine

KW - Female

KW - Immunohistochemistry

KW - Immunotoxins

KW - Mice

KW - Mice, Inbred BALB C

KW - Peritoneum

KW - Radioimmunotherapy

KW - Radiopharmaceuticals

U2 - 10.1089/cbr.2012.1184

DO - 10.1089/cbr.2012.1184

M3 - Journal article

VL - 27

SP - 353

EP - 364

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 6

ER -

ID: 36837471